Located on the ground floor of the Wireless Centre at the Hong Kong Science and Technology Park in Shatin, the office covers an area of over 13,000 square feet with total 14 staffs. PPI is owned by Lee’s Pharmaceuticals, China Opportunity, a renowned fund in China and Sigma-tau. PPI acquire certain assets of and the global interest in Zingo and its powder intradermal injection system. Zingo, also named Lidocaine Hydrochloride Monohydrate, is a new kind of analgesic applied on intact skin to provide painkilling effect prior to venipuncture and intravenous cannulation. Zingo, which has received approval for sales from Food and Drug Administration (FDA) in the United States, is used for partial analgesia prior to veni-puncture and intravenous cannulation for both kids and adults. PPI will focus on manufacturing, developing and selling Zingo and related products.
Mr. Geoffrey F. Woodhead, Assistant Commissioner of Innovation and Technology Commission, Mr. E Anthony Tan, CEO of Hong Kong Science and Technology Park, Mr. Ugo Di Francesco, CEO of Sigma-tau, Mr. Niccolo Magnoni and Mr. Fabio De Rosa, Director of PPI, together with Board members of Lee’s Pharmaceutical, Mr. Lee Siu Fong, Chairman of Lee’s Pharmaceutical, Ms. Leelalertsuphakun Wanee, Dr. Benjamin Li and Mr. Mauro Bove, hosted the grand opening ceremony.
Dr. Benjamin Li, CEO of Lee’s Pharmaceutical said, “I am very pleased to witness the establishment of PPI’s first manufacturing base and would like to extend my gratitude to my partner for its continuous support and trust. The opening marks the success of the production and development business of Lee’s Pharmaceutical. The Board expects the business of PPI to grow in the medium to long run. This transaction represents a good investment opportunity for the Group and a more solid foundation for future growth.”
Powder is an associate of Lee’s Group and will be engaged in the production of Zingo™ (Lidocaine Hydrochloride Monohydrate), a novel pharmaceutical product for pain management which is a combination drug device indicated for use on intact skin to provide local analgesia prior to veni-puncture and intravenous cannulation.
Powder is an associate of...
Milan and Hong Kong, March 15, 2010—Lee’s Pharmaceutical Holdings Limited (GEM Stock: 8221: Website: www.leespharm.com) today announced in conjunction with Recordati S.p.A. (RECI.MI, REC IM, ISIN IT0003828271. Website: www.recordati.com), a European pharmaceutical group, the execution of a License and Supply Agreement for Recordati’s original product, Zanidip® (lercanidipine), in China. The agreement grants Leespharm an exclusive license to market and sell, Zanidip® (lercanidipine tablets) for the treatment of hypertension in the People’s Republic of China.
Milan and Hong Kong, March 15, 2010—Lee’s Pharmaceutical Holdings Limited (GEM Stock: 8221: Website: www.leespharm.com) today announced in conjunction...
San Francisco, California and Hong Kong, November 18, 2009--Jennerex, Inc., a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced in conjunction with Lee’s Pharmaceutical Holdings (HK Stock code: 8221), the execution of a collaboration and license agreement for Jennerex’s lead product candidate, JX-594, in certain Asian territories. Lee’s is a fully integrated pharmaceutical group with operations in People’s Republic of China (PRC), Hong Kong and Macau.
San Francisco, California and Hong Kong, November 18, 2009--Jennerex, Inc., a clinical-stage biotherapeutics company developing a...
Somatostatin was first discovered in hypothalamic extracts and identified as a hormone that inhibited secretion of growth hormone. Subsequently, Somatostatin was found to be secreted by a broad range of tissues, including pancreas, intestinal tract and regions of the central nervous system outside the hypothalamus. Somonal® consists of Somatostatin freeze dried ampoules containing 3 mg of the active substance for dissolution purpose, is indicated for used clinically to treat carcinoid syndrome, enterocutaneous and pancreatic fistula, VIPomas, glucagonomas, severe esophageal varices bleeding.
Somatostatin is widely prescribed in China for acute variceal bleeding. Due to the high prevalence of HBV infection, China has a relatively high number of people suffered from cirrhosis and the subsequent acute esophageal varices bleeding caused by portal vein hypertension. The market for product like Somatostatin in China is quite attractive.
"We're extremely pleased to establish this distribution partnership with GP-Pharm S.A.,," stated Dr. Benjamin Li, the Chief Executive Officer of the Group. "This is the seventh product so far we have licensed-in for distribution in China from our partners in Italy and Spain. This product will allow the Group to enter into a new therapeutic area." The Group believe that successful implementation of this strategy will further expand its market shares, enrich its product pipeline and to broaden its revenue base.
GP-Pharm P.A. is a pharmaceutical company based in Spain within the Lipotec Group whose foundation dates back from 2001. The company is undertaking the pharmaceutical and the clinical development of new products containing hormones and Cytotoxic drugs.
Lee's Pharmaceutical Group, as a research-driven and market-oriented biopharmaceutical group, is actively pursuing for developing proprietary products and licensing technology/product from overseas prestigious biopharmaceutical institutions and companies.
Safe Harbor Statement
The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.
For further information, please contact:
This clinical study was designed to assess safety, tolerability and effective of Yallaferon® for the treatment of patients with cervicitis and cervical erosion. This multi-centers, randomized double-blind, placebo-controlled clinical trial, involving 320 patients was initiated in September 2004. The trial was conducted at eight leading hospitals in three major cities of the PRC, namely Beijing, Shanghai and Guangzhou....
The goal of this clinical study was to demonstrate that Eyprotor® is safe and effective for the clinical treatment of patients with corneal epithelium abrasion. This multi-centers, randomized double-blind, placebo-controlled clinical trial involved 240 patients was initiated in January 2005. This clinical trial was conducted at five leading ophthalmology centers in the PRC, led by Zhongshan Ophthalmology Centre, Zhongshan University ("中山大学中山眼科中心"). The study has been successfully completed in April 2005, and a meeting has been held in Auhui province, China on 2nd May 2005 by principal investigators, to prepare and review the report of clinical trial….